跳至主要内容
临床试验/NCT01555086
NCT01555086Unknown不适用

Prospective Randomized Study to Compare a Limited Versus Extended Pelvic Lymphadenectomy During Prostatectomy

Association of Urologic Oncology (AUO)10 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2011年8月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
500
试验地点
10
主要终点
PSA-progress

研究概览

简要总结

This study examines Limited versus extended pelvic lymphadenectomy.

详细描述

This study is meant to show if the extension of lymphadenectomy during prostatectomy has an influence of outcome of patients. Patients with indication to prostatectomy due to prostate cancer will be included.

Both extensions of lymphadenectomy are used in hospitals as a free choice. This study shell show if one method is more effective than the other.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • stamp bioptic secured prostate cancer with intermediate or high risk profile (defined as Gleason-Score 7-10 or PSA > 10 ng/ml)
  • locally-operable tumor according to DRU/TRUS
  • negative bone scan
  • negative CT abdomen / pelvis
  • general condition according to Karnofsky >/= 80%
  • written consent of the patient
  • adequate hematological, renal and coagulation physiological functions
  • Patient compliance and geographic proximity to allow adequate follow-up

排除标准

  • Manifest secondary malignancy
  • Secured metastasis by histologically or by imaging
  • Myocardial infarction or stroke within the last 6 months
  • Existing major cardiovascular (grade III - IV according to NYHA), pulmonary (pO2 <60 mmHg), renal, hepatic or hematopoietic (eg severe bone marrow aplasia) diseases
  • Severe active or chronic infections (eg pos. HIV-Ab test, HBs-Ag detection in serum and / or chronic hepatitis)
  • severe psychiatric disease
  • prior chemotherapy (allowed is a preoperative antiandrogen therapy ≤ 3 months)
  • previous pelvic radiotherapy
  • Patients in a closed institution according to an authority or court decision
  • People who are in a dependent relationship or working relationship with the sponsor or investigator
  • simultaneous participation in another clinical trial

结局指标

主要结局

PSA-progress

时间窗: 5 years

3-monthly Follow-up with PSA-measurement in blood

次要结局

  • Comparison of overall survival(5 years)
  • Comparison of morbidity(5 years)

研究者

发起方
Association of Urologic Oncology (AUO)
申办方类型
Other
责任方
Sponsor

研究点 (10)

Loading locations...

相似试验

Prospective Study to Compare a Limited Versus... | 临床试验